Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.5
4.8
Journals
Antibiotics
Special Issues
Novel Targets of Drug Monitoring for Antibiotics
share announcement

Novel Targets of Drug Monitoring for Antibiotics

A special issue of Antibiotics (ISSN 2079-6382).

Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 2936

Special Issue Editor

Prof. Dr. Yasuhiro Tsuji

E-Mail Website
Guest Editor
Laboratory of Clinical Pharmacometrics, Nihon University, Chiba 274-8555, Japan
Interests: clinical pharmacology; pharmacometrics; population pharmacokinetics; artificial intelligence; antimicrobial chemotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Drug monitoring is crucial to successfully curing patients’ infections, as typified by vancomycin. Just over 20 years ago, target concentration intervention (TCI) was distinguished from therapeutic drug monitoring (TDM). Both TCI and TDM can be considered as approaches to centration-controlled dosing of individual patients (Holford, 1999). Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication concentrations in blood. On the other hand, target concentration intervention (TCI) embraces pharmacokinetic and pharmacodynamic concepts and uses the idea of a target effect and associated target concentration to make rational individual dose decisions. This Special Issue aims to publish high-quality manuscripts evaluating the novel target of drug monitoring for antibiotics. In the era of individualized medicine, further research of the safety and efficacy of drug monitoring of antibiotics based on novel targets (e.g., unbound drug concentration, metabolites and/or biomarkers) is warranted.

Dr. Yasuhiro Tsuji
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • therapeutic drug monitoring
  • target concentration intervention
  • individual dose
  • antibiotics
  • dose adjustment

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 892 KiB  
Article
Initially Reduced Linezolid Dosing Regimen to Prevent Thrombocytopenia in Hemodialysis Patients
by Hitoshi Kawasuji, Yasuhiro Tsuji, Chika Ogami, Makito Kaneda, Yushi Murai, Kou Kimoto, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Ippei Sakamaki and Yoshihiro Yamamoto
Antibiotics 2021, 10(5), 496; https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics10050496 - 26 Apr 2021
Cited by 7 | Viewed by 2377
Abstract
This retrospective cohort study investigated the effects of an initially reduced linezolid dosing regimen in hemodialysis patients through therapeutic drug monitoring (TDM). Patients were divided into two groups depending on their initial dose of linezolid (standard dose of 600 mg every 12 h [...] Read more.
This retrospective cohort study investigated the effects of an initially reduced linezolid dosing regimen in hemodialysis patients through therapeutic drug monitoring (TDM). Patients were divided into two groups depending on their initial dose of linezolid (standard dose of 600 mg every 12 h or initially reduced dose of 300 mg every 12 h/600 mg every 24 h). The cumulative incidence rates of thrombocytopenia and severe thrombocytopenia were compared between both groups using the Kaplan–Meier method and log-rank test. Eleven episodes of 8 chronic hemodialysis patients were included; 5 were in the initially reduced-dose group. Thrombocytopenia developed in 81.8% of patients. The cumulative incidence rates of thrombocytopenia and severe thrombocytopenia in the initially reduced-dose group were significantly lower than in the standard-dose group (p < 0.05). At the standard dose, the median linezolid trough concentration (Cmin) just before hemodialysis was 49.5 mg/L, and Cmin at the reduced doses of 300 mg every 12 h and 600 mg every 24 h were 20.6 mg/L and 6.0 mg/L, respectively. All five episodes underwent TDM in the standard-dose group required dose reduction to 600 mg per day. Our findings indicate that initial dose reduction should be implemented to reduce the risk of linezolid-induced thrombocytopenia among hemodialysis patients. Full article
(This article belongs to the Special Issue Novel Targets of Drug Monitoring for Antibiotics)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop